A phase 1/phase 2 study will evaluate the efficacy and safety of azeliragon for patients refractory to first-line treatment for metastatic pancreatic cancer.
We’re sorry, but an unexpected error has occurred.
Please refresh your browser and try again. If this error persists, please contact ITSupport@wyanokegroup.com for assistance.
Would you like to receive email reminders to complete your saved activities from Healio CME?
Activity saved! You'll receive reminders to complete your saved activities from Healio CME.
